Bicycle Therapeutics plc
corporate_fare Company Profile
Bicycle Therapeutics plc (NASDAQ:BCYC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for BCYC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for BCYC spans 10-Q, 8-K, PRE 14A, 10-K.
Recent high-impact activity:
- Bicycle Therapeutics Narrows Q3 Loss to $10.5M as Bayer Revenue Lifts Top Line
- Bicycle Therapeutics Narrows Q2 Loss, Extends Cash Runway to 2030
- Bicycle Therapeutics Q2 2026: $50.3M Loss, Bayer Collaboration Terminated, Pipeline Reprioritized
- Bicycle Therapeutics' Duravelo-2 Trial Shows Lower Toxicity, Comparable Efficacy in mUC
- Bicycle Therapeutics Reports Positive Phase 2 Duravelo-2 Data for Zelenectide in Urothelial Cancer
Financial Snapshot
Short Interest & Short Volume
8.38 days to coverFINRA reported short interest of 3,858,686 shares in BCYC as of the October 30, 2026 settlement, a 11.8% increase from the prior period — about 8.4 days to cover at its recent average daily volume. On November 20, 2026, 57.0% of BCYC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.